PL442854A1 - Preparation containing vitamin D3, hard enteric gel capsule containing the vitamin D3 preparation and method of its preparation - Google Patents
Preparation containing vitamin D3, hard enteric gel capsule containing the vitamin D3 preparation and method of its preparationInfo
- Publication number
- PL442854A1 PL442854A1 PL442854A PL44285422A PL442854A1 PL 442854 A1 PL442854 A1 PL 442854A1 PL 442854 A PL442854 A PL 442854A PL 44285422 A PL44285422 A PL 44285422A PL 442854 A1 PL442854 A1 PL 442854A1
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- vitamin
- inulin
- lecithin
- gel capsule
- Prior art date
Links
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title abstract 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 title abstract 5
- 235000005282 vitamin D3 Nutrition 0.000 title abstract 5
- 239000011647 vitamin D3 Substances 0.000 title abstract 5
- 229940021056 vitamin d3 Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 title 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 3
- 229920001202 Inulin Polymers 0.000 abstract 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 3
- 229940029339 inulin Drugs 0.000 abstract 3
- 229940067606 lecithin Drugs 0.000 abstract 3
- 235000010445 lecithin Nutrition 0.000 abstract 3
- 239000000787 lecithin Substances 0.000 abstract 3
- 239000002502 liposome Substances 0.000 abstract 3
- 239000000232 Lipid Bilayer Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004211 gastric acid Anatomy 0.000 abstract 1
- 239000007902 hard capsule Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
Przedmiotem zgłoszenia jest preparat zawierający witaminę D3 w postaci proszku, w którym dwuwarstwa lipidowa liposomów zawiera lecytynę, który to preparat zawiera inulinę jako stabilizator, przy czym stosunek wagowy witaminy D3 do lecytyny mieści się w zakresie od 1:50 do 1:100, natomiast stosunek wagowy lecytyny do inuliny mieści się w zakresie od 1:0,1 do 1:5. Obecność inuliny stabilizuje preparat liposomów i zapobiega tworzeniu agregatów liposomów, szczególnie w warunkach odpowiadających warunkom kwasu żołądkowego. Zgłoszenie dostarcza również twardej kapsułki zawierającej preparat witaminy D3 według wynalazku oraz sposobu jego wytwarzania.The subject of the application is a preparation containing vitamin D3 in the form of powder, in which the lipid bilayer of liposomes contains lecithin, which preparation contains inulin as a stabilizer, and the weight ratio of vitamin D3 to lecithin ranges from 1:50 to 1:100, while the ratio the weight ratio of lecithin to inulin ranges from 1:0.1 to 1:5. The presence of inulin stabilizes the liposome preparation and prevents the formation of liposome aggregates, especially under conditions corresponding to those of gastric acid. The application also provides a hard capsule containing the vitamin D3 preparation according to the invention and a method of preparing it.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL442854A PL442854A1 (en) | 2022-11-16 | 2022-11-16 | Preparation containing vitamin D3, hard enteric gel capsule containing the vitamin D3 preparation and method of its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL442854A PL442854A1 (en) | 2022-11-16 | 2022-11-16 | Preparation containing vitamin D3, hard enteric gel capsule containing the vitamin D3 preparation and method of its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL442854A1 true PL442854A1 (en) | 2024-05-20 |
Family
ID=91128857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL442854A PL442854A1 (en) | 2022-11-16 | 2022-11-16 | Preparation containing vitamin D3, hard enteric gel capsule containing the vitamin D3 preparation and method of its preparation |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL442854A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491499A (en) * | 2009-02-19 | 2009-07-29 | 陶灵刚 | Composite liposome for injection containing 12 vitamins and preparation method thereof |
| WO2020019043A1 (en) * | 2018-07-25 | 2020-01-30 | Castilho Andre Moreira | Pharmaceutical, cosmetic or food products and use of nanoparticles containing vitamin d |
| CN113018264A (en) * | 2021-02-05 | 2021-06-25 | 澳汀斯（广州）生物医药科技有限公司 | Vitamin-encapsulated nano liposome preparation and preparation method thereof |
-
2022
- 2022-11-16 PL PL442854A patent/PL442854A1/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491499A (en) * | 2009-02-19 | 2009-07-29 | 陶灵刚 | Composite liposome for injection containing 12 vitamins and preparation method thereof |
| WO2020019043A1 (en) * | 2018-07-25 | 2020-01-30 | Castilho Andre Moreira | Pharmaceutical, cosmetic or food products and use of nanoparticles containing vitamin d |
| CN113018264A (en) * | 2021-02-05 | 2021-06-25 | 澳汀斯（广州）生物医药科技有限公司 | Vitamin-encapsulated nano liposome preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| AFINJUOMO F, ABDELLA S, YOUSSEF SH, SONG Y, GARG S.: "PHARMACEUTICALS (BASEL). 2021 AUG 26;14(9):855. DOI: 10.3390/PH14090855.", INULIN AND ITS APPLICATION IN DRUG DELIVERY. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY150500A (en) | Stable nutritional powder | |
| EP4122451A8 (en) | Small liposomes for delivery of immunogen-encoding rna | |
| WO2012001604A3 (en) | Solid core coacervated capsules | |
| BR112017028300A2 (en) | nutritional composition, coffee cream, methods for making micellar casein and for preparing a nutritional composition | |
| ZA202101465B (en) | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery | |
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| MX2020014051A (en) | Lipid emulsion for parenteral administration. | |
| PL442854A1 (en) | Preparation containing vitamin D3, hard enteric gel capsule containing the vitamin D3 preparation and method of its preparation | |
| EP2663295A2 (en) | Highly concentrated liquid acetaminophen solutions | |
| CO2021005370A2 (en) | Composition of non-dairy hard cheese and process for its preparation | |
| AR077264A1 (en) | METHOD FOR PRODUCING A PHYSTESTEROL ESTER AND / OR A PHYTOESTANOL ESTER | |
| PL442904A1 (en) | Preparation containing glutathione, hard gastro-resistant capsule containing the glutathione preparation, and method of its production | |
| FI20075739A0 (en) | Microcapsulated liposome compositions | |
| PL439126A1 (en) | Vitamin B12 preparation and method of its production | |
| PL440166A1 (en) | Vitamin B complex preparation, a gastro-resistant hard gel capsule containing a vitamin preparation and method for its production | |
| PL439306A1 (en) | Liposomal preparation of zinc and copper and method of preparing it | |
| PL440164A1 (en) | Vitamin preparation containing vitamins A, D, E, K, a gastroresistant hard gelatin capsule containing a vitamin preparation and method for its production | |
| PH12020550513A1 (en) | Composition of docetaxel liposomal injection with high drug loading | |
| CN108883204A8 (en) | Lipid microbubble and preparation method thereof | |
| ITRM20050592A1 (en) | LIPID COMPOSITION THAT PRESENTS NUTRITIONAL AND ORGANOLEPTIC PROPERTIES OF INTEREST. | |
| US10640730B2 (en) | Oil composition and oxidation inhibiting method of oil | |
| MX2021013842A (en) | Pharmaceutical composition of a weak acid drug and methods of administration. | |
| WO2011074782A3 (en) | Liposome composition, preparation method thereof, and usage of the composition as pneumonia vaccine | |
| WO2012117385A3 (en) | Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it | |
| JP2017516820A (en) | Homogeneous formulation for oral administration comprising omega-3 polyunsaturated fatty acid and resveratrol |